Peroxisome proliferator-activated receptors: Vascular and cardiac effects in hypertension

Hypertension

Volumn 42, Issue 4 II, 2003, Pages 664-668

  Schiffrin, Ernesto L ^a   Amiri, Farhad ^b   Benkirane, Karim ^b   Iglarz, Marc ^b   Diep, Quy N ^b  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^b NONE

Author keywords

Arteries; Cardiovascular diseases; Fibrosis; Heart; Remodeling; Transcription; Vasculature

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; FIBRIC ACID DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; REACTIVE OXYGEN METABOLITE; RETINOID X RECEPTOR; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR EFFECT; CONFERENCE PAPER; CONTROLLED STUDY; DIMERIZATION; DRUG EFFECT; GENE TARGETING; HEART FUNCTION; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; HYPERTENSION; INSULIN SENSITIVITY; NONHUMAN; PRIORITY JOURNAL; RAT; VASCULAR SMOOTH MUSCLE;

ANIMALS; BLOOD VESSELS; HEART DISEASES; HYPERTENSION; MICE; MYOCARDIUM; RATS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS;

EID: 85026134753     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000084370.74777.B6     Document Type: Conference Paper

References (56)

1. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature. 1990;347:645-650.
2. Law RE, Hsueh WA. PPARγ and atherosclerosis: effects on cell growth and movement. Arterioscler Thromb Vasc Biol. 2001;21:1891-1895.
3. Delerive P, Fruchart C, Staels B. Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol. 2001;169:453-459.
4. Dreyer C, Krey G, Keller H, Givel F, Helftenbein G, Wahli W. Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors. Cell. 1992;68:879-887.
5. Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ, Umesono K, Evans RM. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA. 1994;91:7355-7359.
6. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, -β, and -γ in the adult rat. Endocrinology. 1996;137:354-366.
7. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell. 1994;79:1147-1156.
8. Gilde AJ, van der Lee KAJM, Willemsen PHM, Chinetti G, van der Leij FR, van der Vusse GJ, Staels B, van Bilsen M. Peroxisome proliferators activated receptor (PPAR) a and PPARβ/δ, but not PPARγ, modulate the expression of genes involved in cardiac lipid metabolism. Circ Res. 2003;92:518-524.
9. Chawla A, Lee CH, Barak Y, He W, Rosenfeld J, Liao D, Han J, Kang H, Evans RM. PPARδ is a very low-density lipoprotein sensor in macrophages. Proc Natl Acad Sci U S A. 2003;100:1268-1273.
10. Tugwood JD, Issemann I, Anderson RG, Bundell KR, McPheat WL, Green S. The mouse peroxisome proliferator activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene. EMBO J. 1992;11:433-439.
11. Ijpenberg A, Jeannin E, Wahli W, Desvergne B. Polarity and specific sequence requirements of peroxisome proliferator-activated receptor (PPAR)/retinoid X receptor heterodimer binding to DNA: a functional analysis of the malic enzyme gene PPAR response element. J Biol Chem. 1997;272:20108-20117.
12. Llopis J, Westin S, Ricote M, Wang Z, Cho CY, Kurokawa R, Mullen TM, Rose DW, Rosenfeld MG, Tsien RY, Glass CK, Wang J. Ligand-dependent interactions of coactivators steroid receptor coactivator-1 and peroxisome proliferator-activated receptor binding protein with nuclear hormone receptors can be imaged in live cells and are required for transcription. Proc Natl Acad Sci U S A. 2000;97:4363-4368.
13. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev. 1999;20:649-688.
14. Bishop-Bailey D. Peroxisome proliferator-activated receptors in the cardiovascular system. Br J Pharmacol. 2000;129:823-834.
15. Inoue I, Shino K, Noji S, Awata T, Katayama S. Expression of peroxisome proliferator-activated receptor α (PPARα) in primary cultures of human vascular endothelial cells. Biochem Biophys Res Commun. 1998;246:370-374.
16. Satoh H, Tsukamoto K, Hashimoto Y, Hashimoto N, Togo M, Hara M, Maekawa H, Isoo N, Kimura S, Watanabe T. Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPARγ on vascular endothelial function. Biochem Biophys Res Commun. 1999;254:757-763.
17. Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, Najib J, Maclouf J, Tedgui A. Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators. Nature. 1998;393:790-793.
18. Chinetti G, Griglio S, Antonucci M, Torra IP, Delerive P, Majd Z, Fruchart JC, Chapman J, Najib J, Staels B. Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages. J Biol Chem. 1998;273:25573-25580.
19. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature. 1998;391:79-82.
20. Diep QN, Intengan HD, Schiffrin EL. Endothelin-1 attenuates ω-3 fatty acid-induced apoptosis by inhibition of caspase 3. Hypertension. 2000;35:287-291.
21. Diep QN, Touyz RM, Schiffrin EL. Docosahexaenoic acid, a peroxisome proliferator-activated receptor-α activator, induces apoptosis in vascular smooth muscle cells by activation of p38 mitogen-activated protein kinase. Hypertension. 2000;36:851-855.
22. Madej A, Okopien B, Kowalski J, Zielinski M, Wysocki J, Szygula B, Kalina Z, Herman ZS. Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb. Int J Clin Pharmacol Ther. 1998;36:345-349.
23. Marx N, Sukhova GK, Collins T, Libby P, Plutzky J. PPARα activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation. 1999;99:3125-3131.
24. Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ, Fruchart JC, Tedgui A, Haegeman G, Staels B. Peroxisome proliferator-activated receptor α negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-κB and AP-I. J Biol Chem. 1999;274:32048-32054.
25. Poynter ME, Daynes RA. Peroxisome proliferator-activated receptor α activation modulates cellular redox status, represses nuclear factor-κB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem. 1998;273:32833-32841.
26. Diep QN, Amiri F, Touyz RM, Cohn JS. Endemann D, Schiffrin EL. PPARα activator effects on Ang II-induced vascular oxidative stress and inflammation. Hypertension. 2002;40:866-871.
27. Law RE, Goetze S, Xi X-P, Jackson S, Kawano Y, Demer L, Fishbein MC, Meehan WP, Hsueh WA. Expression and function of PPARγ in rat and human vascular smooth muscle cells. Circulation. 2000;101:1311-1318.
28. Diep QN, Schiffrin EL. Increased expression of peroxisome proliferator-activated receptor-α and -γ in blood vessels of spontaneously hypertensive rats. Hypertension. 2001;38:249-254.
29. Jiang C, Ting AT, Seed B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391:82-86.
30. Ricote M, Huang JT, Welch JS, Glass CK. The peroxisome proliferator-activated receptorγ (PPARγ) as a regulator of monocyte/macrophage function. J Leukoc Biol. 1999;66:733-739.
31. Ricote M, Huang J, Fajas L, Li A, Welch J, Najib J, Witztum JL, Auwerx J, Palinski W, Glass CK. Expression of the peroxisome proliferator-activated receptorγ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci U S A. 1998;95:7614-7619.
32. Pasceri V, Wu HD, Willerson JT, Yeh ET. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-γ activators. Circulation. 2000;101:235-238.
33. Jozkowicz A, Dulak J, Prager M, Nanobashvili J, Nigisch A, Winter B, Weigel G, Huk I. Prostaglandin-J2 induces synthesis of interleukin-8 by endothelial cells in a PPAR-γ-independent manner. Prostaglandins Other Lipid Mediat. 2001;66:165-177.
34. Takata Y, Kitami Y, Yang ZH, Nakamura M, Okura T, Hiwada K. Vascular inflammation is negatively autoregulated by interaction between CCAAT/enhancer-binding protein-δ and peroxisome proliferator-activated receptor-γ. Circ Res. 2002;91:427-433.
35. Diep QN, El Mabrouk M, Cohn JS, Endemann D, Amiri F, Virdis A, Neves MF, Schiffrin EL. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-γ. Circulation. 2002;105:2296-2302.
36. Iglarz M, Touyz RM, Amiri F, Lavoie MF, Diep QN, Schiffrin EL. Effect of peroxisome proliferator-activated receptor-α and -γ activators on vascular remodeling in endothelin-dependent hypertension. Arterioscler Thromb Vasc Biol. 2003;23:45-51.
37. Aitman TJ, Glazier AM, Wallace CA, Cooper LD, Norsworthy PJ, Wahid FN, Al-Majali KM, Trembling PM, Mann CJ, Shoulders CC, Graf D, St Lezin E, Kurtz TW, Kren V, Pravenec M, Ibrahimi A, Abumrad NA, Stanton LW, Scott J. Identification of Cd36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats. Nat Genet. 1999;21:76-83.
38. Brandt JM, Djouadi F, Kelly DP. Fatty acids activate transcription of the muscle carnitine palmitoyltransferase I gene in cardiac myocytes via the peroxisome proliferator-activated receptor α. J Biol Chem. 1998;273:23786-23792.
39. Djouadi F, Brandt JM, Weinheimer CJ, Leone TC, Gonzalez FJ, Kelly DP. The role of the peroxisome proliferator-activated receptor α (PPAR α) in the control of cardiac lipid metabolism. Prostaglandins Leukot Essent Fatty Acids. 1999;60:339-343.
40. Watanabe K, Fujii H, Takahashi T, Kodama M, Aizawa Y, Ohta Y, Ono T, Hasegawa G, Naito M, Nakajima T, Kamijo Y, Gonzalez FJ, Aoyama T. Constitutive regulation of cardiac fatty acid metabolism through peroxisome proliferator-activated receptor α associated with age-dependent cardiac toxicity. J Biol Chem. 2000;275:22293-22299.
41. Barger PM, Brandt JM, Leone TC, Weinheimer CJ, Kelly DP. Deactivation of peroxisome proliferator-activated receptor-α during cardiac hypertrophic growth. J Clin Invest. 2000;105:1723-1730.
42. Takano H, Nagai T, Asakawa M, Toyozaki T, Oka T, Komuro I, Saito T, Masuda Y. Peroxisome proliferator-activated receptor activators inhibit lipopolysaccharide-induced tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes. Circ Res. 2000;87:596-602.
43. Ogata T, Miyauchi T, Sakai S, Irukayama-Tomobe Y, Goto K, Yamaguchi I. Stimulation of peroxisome-proliferator-activated receptor α (PPARα) attenuates cardiac fibrosis and endothelin-1 production in pressure-overloaded rat hearts. Clin Sci. 2002;103 (suppl 1):284S-288S
44. Maruyama S, Kato K, Kodama M, Hirono S, Fuse K, Nakagawa O, Nakazawa M, Miida T, Yamamoto T, Watanabe K, Aizawa Y. Fenofibrate, a peroxisome proliferator-activated receptor alpha activator, suppresses experimental autoimmune myocarditis by stimulating the interleukin-10 pathway in rats. J Atheroscler Thromb. 2002;9:87-92.
45. Diep QN, Benkirane K, Schiffrin EL. PPARα activator fenofibrate inhibits myocardial fibrosis and inflammation in angiotensin II-infused rats. Hypertension. 2002;40:388. Abstract.
46. Kelly DP. PPARs of the heart. Circ Res. 2003;92:482-484.
47. Yamamoto K, Ohki R, Lee RT, Ikeda U, Shimada K. Peroxisome proliferator-activated receptor γ activators inhibit cardiac hypertrophy in cardiac myocytes. Circulation. 2001;104:1670-1675.
48. Asakawa M, Takano H, Nagai T, Uozumi H, Hasegawa H, Kubota N, Saito T, Masuda Y, Kadowaki T, Komuro IF. Peroxisome proliferator-activated receptor γ plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation. 2002;105:1240-1246.
49. Tsuji T, Mizushige K, Noma T, Murakami K, Ohmori K, Miyatake A, Kohno M. Pioglitazone improves left ventricular diastolic function and decreases collagen accumulation in prediabetic stage of a type II diabetic rat. J Cardiovasc Pharmacol. 2001;38:868-874.
50. Zhu P, Lu L, Xu Y, Schwartz GG. Troglitazone improves recovery of left ventricular function after regional ischemia in pigs. Circulation. 2000;101:1165-1171.
51. Sidell RJ, Cole MA, Draper NJ, Desrois M, Buckingham RE, Clarke K. Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the Zucker fatty rat heart. Diabetes. 2002;51:1110-1117.
52. Yue TL, Chen J, Bao W, Narayanan PK, Bril A, Jiang W, Lysko PG, Gu JL, Boyce R, Zimmerman DM, Hart TK, Buckingham RE, Ohlstein EH, In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone. Circulation. 2001;104:2588-2594.
53. Wooltorton E. Rosiglitazone (Avandia) and pioglitazone (Actos) and heart failure. Can Med Assoc J. 2002;166:219.
54. Purcell NH, Tang G, Yu C, Mercurio F, DiDonato JA, Lin A. Activation of NF-κB is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes. Proc Natl Acad Sci U S A. 2001;98:6668-6673.
55. Diep QN, Benkirane K, Schiffrin EL. Long-term effects of pioglitazone on cardiac hypertrophy, inflammation and fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension. 2002;40:412. Abstract.
56. Wang C-H, Weisel RD, Liu PP, Fedak PWM, Verma S. Glitazones and heart failure: critical appraisal for the clinician. Circulation. 2003;107:1350-1354.